Effectiveness of Ophtascan Screening in Lubumbashi. Pilot Study on Screening for Cancer and Type 2 Diabetes

Authors

  • Dsir Kamba Banza Ecole de Sant Publique-UNILU
  • Robert Mbuli Lukamba Ecole de Sant Publique-UNILU
  • Simon Henry Opio-Emuna Sigma Africa Healthcare LTD
  • Cilundika Phillippe Ecole de Sant Publique-UNILU
  • Amani Chuma UNILU
  • Jean-Paul Mande Ngoy UNILU
  • Dophra Nkulu Ngoy UNILU
  • Albert Tambwe Nkoy Mwembo Ecole de Sant Publique-UNILU
  • Oscar Numbi Luboya Ecole de Sant Publique-UNILU

DOI:

https://doi.org/10.47941/ijhmnp.1705

Keywords:

Effectiveness-ophtascan-screening- cancer-type 2 diabetes

Abstract

Purpose: Screening and early treatment are the best strategy for controlling cancer and type 2 diabetes (T2DM). Based on artificial intelligence, new software Ophtascan allows the early detection of the following cancers: cervix, endometrium, breast, prostate, lung as well as type 2 diabetes, from the image of the eyes. The objectives of this study were to test the reliability of the test in the detection of type 2 diabetes and to present the prevalence of oncological pathologies detected.

Methodology: screening was carried out in two stages: a technical test of the program and mass screening at the University Clinics of Lubumbashi and the Sendwe Hospital of Lubumbashi among volunteers from April 2023 to July 2023.

Findings: Of the 98 volunteers screened including 32 men and 66 women, the risk of the following cancers was detected by Ophtascan: in men, 12.5%, 28% and 6% respectively for the prostate, lung (pre-cancer) and lung while in women we had 1.5%, 6%, 3%, 4.5% and 3% respectively for cervix (pre-cancer), cervical cancer, endometrial, breast (pre- cancer) and breast. This cancer screening trial was not accompanied by clinical confirmation of detected diseases due high cost and practical problems. T2DM trial was accompanied by lab blood test for confirmation of results. Proved sensitiviy of Ophtascan for T2DM achieved 91% within blind clinical trial and 100% within technical trial, and 72% of screened people did not suspect they had this disease, detected by Ophtascan.

Unique Contribution to theory, Policy and Practice: Ophtascan is feasible in our environment and seems to have high reliability for the detection of type 2 diabetes as screening tool. Ophtascan certainly detected most of the targeted cancers, but the low number of cases does not allow solid conclusions to be drawn. The difficulty of validation for all types of cancer mentioned above due to its high cost for patients, we propose to carry out a new pilot research project which will focus on cervical cancer, for which early treatment is possible at a low cost in our environment.

Downloads

Download data is not yet available.

Author Biographies

Dsir Kamba Banza , Ecole de Sant Publique-UNILU

Dpartement de Sant Publique (Unit de la Sant Mère-Enfant)/Facult de Mdecine- UNILU

Cilundika Phillippe , Ecole de Sant Publique-UNILU

Dpartement de Sant Publique (Unit de la Sant Mère-Enfant)/Facult de Mdecine- UNILU

Amani Chuma , UNILU

Dpartement de Gyncologie et Obsttrique de la Facult de Mdecine

Jean-Paul Mande Ngoy , UNILU

Dpartement de Mdecine Interne de la Facult de Mdecine

Dophra Nkulu Ngoy , UNILU

Dpartement de Mdecine Interne de la Facult de Mdecine

Albert Tambwe Nkoy Mwembo , Ecole de Sant Publique-UNILU

Dpartement de Sant Publique (Unit de la Sant Mère-Enfant)/Facult de Mdecine- UNILU

Oscar Numbi Luboya , Ecole de Sant Publique-UNILU

Dpartement de Sant Publique (Unit de la Sant Mère-Enfant)/Facult de Mdecine- UNILU

References

.https://cdn.who.int/media/docs/default-source/country-profiles/diabetes/cod_en.pdf?sfvrsn=8759f61d_7&download=true

International Diabetes Foundation. Democratic Republic of Congo [Internet]. [cited 2020 Sep 9]. https://www.idf.org/our-network/regions-members/africa/members/21-democratic-republic-of-congo.html

Ministry of Public Health of the Democratic Republic of the Congo. [Standards and guidelines for diabetes management] [Internet]. [cited 2021 May 1]. https://extranet.who.int/ncdccs/Data/COD_B6_NV_Draft%20final_Normes%20Diab%C3%A8te_09_11_13final%20(2).pdf 4. 4.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467973/

https://www.nature.com/articles/s41598023297431https://www.iaea.org/newscenter/news/strengthening-cancer-care-in-the-democraticrepublic-of-the-congo-experts-recommend-decentralizing-services

https://cdn.who.int/media/docs/default-source/country-profiles/cervical-cancer/cervical-cancer-cod-2021-country-profile-en.pdf?sfvrsn=f8a6d07d_36&download=true

Cavagnolli G, Comerlato J, Comerlato C, et al. HbA1c measurement for the diagnosis of diabetes: is it enough? Diabet Med 2011;28:31-5.

Organisation Mondiale de la Sant. Rapport mondial sur le diabète. Http://apps.who.int/ iris/bitstream/handle/10665/204875/WHO_NMH_NVI_16.3_fre.pdf?sequence=1. 2016, consulted on February, 18th,2019.

Mshinda KD, Kayembe KP, Mapatano MA.(2012). Prvalence du cancer en Rpublique Dmocratique du Congo : donnes anatomo-pathologiques aux Cliniques Universitaires de Kinshasa et à l'Hôpital de Rfrence de Kinshasa. Annales Africaines de Mdecine ;Vol 3 : Juin 2012

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J Clin 2018;68:394-424. pmid:30207593

.11.Gantsev S.K., Schaller G., Gantsev K.S., Plikhta A.N., Kzyrgalin S.R., Rustamkhanov R.A. Neuroendocrine Breast Cancer. Clinical Observation. Personalized Approach. Creative surgery and oncology. 2021;11(2):144-148. https://doi.org/10.24060/2076-3093-2021-11-2-144-148

Downloads

Published

2024-02-27

How to Cite

Banza , D. K., Lukamba, R. M., Opio-Emuna , S. H., Phillippe , C., Chuma , A., Ngoy , J.-P. M., … Luboya , O. N. . (2024). Effectiveness of Ophtascan Screening in Lubumbashi. Pilot Study on Screening for Cancer and Type 2 Diabetes . International Journal of Health, Medicine and Nursing Practice, 6(2), 44–51. https://doi.org/10.47941/ijhmnp.1705

Issue

Section

Articles